📰 Bio Developments News
Page 24 - Bio Developments News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Bio Developments. Real-time updates on events, politics, business and more.
August 14, 2023
Ginkgo Bioworks, a platform for cell programming and biosecurity, has announced a new partnership with Boehringer Ingelheim.
August 10, 2023
Lonza has launched the Nebula Absorbance Reader, a new absorbance microplate reader, which joins the company’s portfolio of optimized instruments for streamlined endotoxin and pyrogen testing.
August 10, 2023
Evox Therapeutics, an exosome therapeutics company, has announced the publication of its research identifying novel exosome scaffold proteins that significantly improve drug loading into exosomes for therapeutic purposes.
August 8, 2023
Terumo Blood and Cell Technologies have announced US Food and Drug Administration (FDA) clearance of the Reveos Automated Whole Blood Processing System.
August 7, 2023
A promising shift towards the development of antibody-drug conjugates (ADC) for cancer treatment is taking place in the pharmaceutical industry.
August 7, 2023
BlueRock Therapeutics, a clinical stage cell therapy company, and bit.bio, the company coding human cells for novel cures, have announced a collaboration and option agreement for the discovery and manufacture of iPSC-derived regulatory T cells (Tregs) for use in creating therapeutics.
August 7, 2023
Evox Therapeutics, an exosome therapeutics company, has announced a research collaboration and option agreement with the Icahn School of Medicine at Mount Sinai in New York, US.
August 1, 2023
Epsilogen, a leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, has published phase 1 data from the first ever clinical trial of an IgE antibody therapeutic in Nature Communications.
July 31, 2023
IO Biotech, a clinical-stage biopharma company developing novel, immune-modulating cancer vaccines based on its T-win technology platform, has dosed the first patient in its phase 1 bladder cancer trial.
July 31, 2023
Boston-based pharma company Ratio Therapeutics has initiated dosing in a phase 1 study evaluating the pharmacokinetics, biodistribution and radiation dosimetry of a novel fibroblast activation protein-alpha (FAP)-targeted radiopharmaceutical, RTX-1363S, for PET imaging in adult healthy volunteers.